Avidity Biosciences

Avidity Biosciences is a biopharmaceutical company specializing in the development of antibody-oligonucleotide conjugates (AOCs) aimed at treating serious diseases. They generate revenue primarily through strategic partnerships, licensing agreements, and the development of proprietary therapies. Founded in 2012, Avidity has made significant strides in advancing its AOC platform, which combines the precision of monoclonal antibodies with the therapeutic potential of oligonucleotides, positioning itself as a leader in the field of targeted genetic medicine.

Recent Posts by Avidity Biosciences

1-20 of 76